<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226407</url>
  </required_header>
  <id_info>
    <org_study_id>CG200745-1-01</org_study_id>
    <nct_id>NCT01226407</nct_id>
  </id_info>
  <brief_title>Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile</brief_title>
  <official_title>Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CrystalGenomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CrystalGenomics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, single dose and phase I study.

      The primary objective: To determine the maximum tolerated dose in Single dose

      The secondary objective: to evaluate the toxicity in administration to determine desirable
      dosing amount for phase II to evaluate tumor response in progressive solid cancer patients to
      evaluate pharmacokinetic/ pharmacodynamic profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Number of Subjects: 28~36, dose escalation (2~6 subject of each step)

        2. Adverse Events will be coded to preferred therm and body system using the CTCAE
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose in Single dose</measure>
    <time_frame>On 22 days after administration</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Solid Tumour</condition>
  <arm_group>
    <arm_group_label>Single Arm for CG200745</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>any progrossive solid cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG200745</intervention_name>
    <description>Multiple administration (IV) over the cycles untile MTD/LTD</description>
    <arm_group_label>Single Arm for CG200745</arm_group_label>
    <other_name>No specific generic name yet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  from 20 years old to 69 years old

          -  diagnosed with progressive solid cancer

          -  In spite of standard chemotherapies, the efficacy of the treatment or life extension
             cannot be expected.

          -  Evaluated 0-1 of ECOG

          -  Expected life duration is within 3 months

        Exclusion Criteria:

          -  Major surgery except tumor-removal surgery received within 2 weeks of screening.

          -  history of CNS metasis

          -  hyper-sensitivy of study drug

          -  pregancy or lactating

          -  administered other HDAC inhibitor within 4 weeks of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae Won Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Asan medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tae Won Kim, MD, PhD</last_name>
    <email>twkimmd@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Won Kim, MD, PhD</last_name>
      <email>twkimmd@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>December 27, 2012</last_update_submitted>
  <last_update_submitted_qc>December 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumour</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

